The Medicare GLP-1 Bridge Program: A Pharmacist's Plain-English Guide

Medicare’s GLP-1 Bridge program began July 1, 2026 and runs through December 31, 2027. For the first time, eligible Medicare drug plan members can get certain GLP-1 medications for weight management, including Wegovy and Zepbound, for a flat $50 monthly copay. The program is run directly by Medicare, not by your drug plan, and it has specific medical eligibility rules.

As a pharmacist by training, I have watched GLP-1 coverage questions frustrate Medicare clients for years. Until now, the answer was simple and disappointing: Medicare drug plans were barred from covering these medications for weight loss alone. The Bridge program changes that, temporarily and with conditions. Here is what it actually does, who qualifies, and where the fine print matters.

What the GLP-1 Bridge program is

The Bridge is a short-term demonstration from the Centers for Medicare and Medicaid Services (CMS). It gives Medicare beneficiaries access to specific GLP-1 drugs when they are prescribed to reduce excess body weight and keep it off. CMS originally planned to follow it with a longer-term model, so the Bridge was set up to carry coverage from July 1, 2026 through December 31, 2027.

Three points make this program unusual:

• Medicare runs it, not your plan. Eligibility decisions, prior authorizations, and claims all go through a single central processor working for CMS. Your Part D plan is not the one saying yes or no.
• The copay is a flat $50 per month for an eligible drug, regardless of which covered medication you take.
• It sits outside your normal Part D benefit. Your plan deductible does not apply to Bridge prescriptions. Just as important, the $50 copays do not count toward your annual Part D out-of-pocket cap ($2,100 in 2026), and Extra Help (the Low-Income Subsidy) does not reduce the $50.

Which drugs are covered

The Bridge covers a short, specific list when prescribed for weight management: Wegovy (injection and tablets), Zepbound (KwikPen), and Foundayo. It does not cover compounded versions.

One clarification that prevents a lot of confusion: if you take a GLP-1 for diabetes, such as Ozempic or Mounjaro, that is regular Part D coverage and always has been. Your plan’s normal formulary, tiers, and copays apply, and those costs do count toward the $2,100 cap. The Bridge only addresses the weight-management use that Part D could not previously cover.

Who qualifies

You must be enrolled in Medicare drug coverage, either a standalone Part D plan or a Medicare Advantage plan that includes drug coverage. On the medical side, CMS set three qualifying paths, based on body mass index (BMI) at the time GLP-1 therapy starts:

Path	BMI	Additional diagnosis required
1	35 or higher	None
2	30 or higher	Heart failure with preserved ejection fraction, uncontrolled high blood pressure (above 140/90 despite two blood pressure medications), or chronic kidney disease stage 3a or above
3	27 or higher	Pre-diabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease

Your prescriber submits the prior authorization and attests that you meet the criteria. If you were already on GLP-1 therapy before the program started, the BMI test looks at when you began therapy, not your BMI today. That detail matters: losing weight on the medication does not disqualify you from the program.

What it costs, honestly

Fifty dollars a month is a dramatic discount from cash prices that often run several hundred dollars or more. Over a full year, that is $600 out of pocket. Two budgeting cautions, though. First, because Bridge copays do not count toward your $2,100 Part D cap, they stack on top of whatever you spend on your other medications rather than helping you reach the cap sooner. Second, the program has an end date. If it expires on December 31, 2027 without a successor, coverage for weight-management GLP-1s could revert to nothing. Do not build a long-term medication plan around a temporary program without a fallback conversation with your prescriber.

How to get started

1. Talk to your doctor about whether you meet one of the three eligibility paths and whether a covered drug fits your health picture.
2. Your prescriber submits the prior authorization to Medicare’s central processor, not to your drug plan.
3. Once approved, fill at a participating pharmacy and pay the $50 copay.
4. Keep your regular Part D plan tuned to your other prescriptions. The Bridge does not change how the rest of your drug list is covered, and plan choice still drives what you pay for everything else. Our Part D guide for Alabama covers how to compare plans by pharmacy and formulary.

The official beneficiary page is at Medicare.gov (search “GLP-1 Bridge” or visit medicare.gov/coverage/weight-loss-drugs), and you can always call 1-800-MEDICARE.

Frequently asked questions

Does the Bridge program cover Ozempic for weight loss?

No. The covered drugs for weight management are Wegovy, Zepbound, and Foundayo. Ozempic remains covered under regular Part D when prescribed for diabetes.

Do I need a special plan to get the $50 copay?

No. You need to be enrolled in any Medicare drug coverage, either a standalone Part D plan or a Medicare Advantage plan with drug coverage, and meet the medical criteria. The program itself is administered directly by Medicare.

Does the $50 copay count toward my Part D out-of-pocket cap?

No. Bridge copays sit outside the normal Part D benefit, so they do not count toward the $2,100 cap in 2026. Your plan deductible also does not apply to Bridge prescriptions.

I have Extra Help. Is my copay lower than $50?

No. The Low-Income Subsidy does not apply inside the Bridge program, so the copay is $50 for everyone who qualifies.

What happens when the program ends?

The Bridge is scheduled to run through December 31, 2027. Whether coverage continues after that depends on future federal decisions. Build a plan B with your prescriber, and if you are comparing drug plans during Annual Enrollment, remember the Bridge is plan-independent, so choose your Part D plan based on your other medications.